Publications by authors named "Hiroomi Tada"

Claim this Profile
A
A novel objective method for discriminating pathological and physiological colorectal uptake in the lower abdominal region using whole-body dynamic F-FDG-PET.
Toyohiro Kato, Hajime Ichikawa, Takayuki Shibutani, Akinobu Kita, Masanori Watanabe, Hiroomi Tada

Ann Nucl Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ex Vivo Drug Sensitivity Correlates with Clinical Response and Supports Personalized Therapy in Pediatric AML.
Debbie C Strachan, Christine J Gu, Ryosuke Kita, Erica K Anderson, Michelle A Richardson, Hiroomi Tada

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.
David J Pulford, Philipp Harter, Anne Floquet, Catherine Barrett, Dong Hoon Suh, Hiroomi Tada

BMC Med Ethics· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.
Chun-Fang Xu, Toby Johnson, Xiaojing Wang, Chris Carpenter, Alan P Graves, Hiroomi Tada

Clin Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Antoinette R Tan, Darlene G Gibbon, Mark N Stein, Diana Lindquist, Jeffery W Edenfield, Hiroomi Tada

Cancer Chemother Pharmacol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Roy S Herbst, Yan Sun, Wilfried E E Eberhardt, Paul Germonpré, Nagahiro Saijo, Hiroomi Tada

Lancet Oncol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pigmented epithelioid melanocytoma.
Jon R Ward, Stephen P Brady, Hiroomi Tada, Nikki A Levin

Int J Dermatol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas.
Rhonda K Yantiss, Bruce A Woda, Gary R Fanger, M Kalos, Giles F Whalen, Hiroomi Tada

Am J Surg Pathol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis